Cite
MLA Citation
Remo Panaccione et al.. “S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study.” American journal of gastroenterology, vol. 116, n.d., p. S348. http://access.bl.uk/ark:/81055/vdc_100144523427.0x00002d